IL-17A-induced NETs are profibrogenic in mice with metabolic dysfunction-associated steatotic liver disease (MASLD)

Mohamed N Abdelnabi1,2, Yousef Maali1,2, Afrooz Dabbaghizadeh1,2

  • 1Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC H2X 0A9, Canada.

Insights

Interleukin-17A-producing neutrophils and neutrophil extracellular traps (NETs) worsen metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis. Targeting IL-17A may offer new therapeutic strategies for MASLD.

Area of Science:

  • Immunology
  • Hepatology
  • Pathology

Background:

  • Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition with few treatment options.
  • Interleukin (IL)-17A is a pro-inflammatory cytokine implicated in MASLD pathogenesis.
  • The role of neutrophils and neutrophil extracellular traps (NETs) in MASLD-related fibrosis is not fully understood.

Purpose of the Study:

  • To investigate the kinetics of IL-17A-producing neutrophils in MASLD-related fibrosis.
  • To examine the impact of IL-17A on NET formation in MASLD.
  • To elucidate the contribution of IL-17A-induced NETs to liver fibrosis progression.

Main Methods:

  • A mouse model of MASLD induced by high-fat diet (HFD) for 15 or 30 weeks.
  • In vitro studies using isolated neutrophils and hepatic stellate cells (HSCs).
  • Assessment of intrahepatic IL-17A-producing neutrophils, NET formation, liver injury, and fibrosis markers.

Main Results:

  • HFD-fed mice showed increased intrahepatic IL-17A-producing neutrophils and NET formation, correlating with liver injury and advanced fibrosis.
  • IL-17A treatment stimulated NET formation in isolated neutrophils.
  • IL-17A-induced NETs activated HSCs, promoted fibrogenic gene expression, and enhanced HSC migration.

Conclusions:

  • IL-17A-producing neutrophils play a significant profibrogenic role in MASLD.
  • IL-17A-induced NET formation contributes to the development and progression of liver fibrosis in MASLD.
  • Targeting IL-17A and NETs presents a potential therapeutic avenue for MASLD.

Related Concept Videos